Sinus Disease in Young Children With Cystic Fibrosis

Key facts

Sponsor

University of California, Los Angeles

Principal Investigator

Daniel M Beswick, MD

University of California, Los Angeles

Intervention

Ivacaftor or elexacaftor/tezacaftor/ivacaftor(drug)

Enrollment

80 enrolled

Eligibility

2-8 years · All sexes

Timeline

2023 – 2026

Study locations (6)

• Children's Hospital Colorado, Aurora, Colorado, United States
• University of Iowa, Iowa City, Iowa, United States
• University of Kansas Medical Center, Kansas City, Kansas, United States
• Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
• University of Vermont, Colchester, Vermont, United States
• University of Virginia, Charlottesville, Virginia, United States

Collaborators

University of Kansas Medical Center · Children's Hospital Medical Center, Cincinnati · University of Iowa · University of Virginia · University of Vermont · University of North Carolina, Chapel Hill · Children's Hospital Colorado

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Genetic digestive tract malformation

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06507956
  Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
  Hospices Civils de Lyon
• RECRUITINGNCT06296394
  Health Outcomes of Parents With Cystic Fibrosis-Aim 2
  University of Pittsburgh
• RECRUITINGPHASE1NCT06154447
  Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNCT05501587
  Measures of Respiratory Health Registry
  University of British Columbia

See all trials for Genetic digestive tract malformation →